id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-1573-0005,FDA,FDA-2013-E-1573,"Determination of Regulatory Review Period for Purposes of Patent
Extension; VERAFLOX",Notice,Determinations,2015-12-10T05:00:00Z,2015,12,2015-12-10T05:00:00Z,2016-02-09T04:59:59Z,2015-12-10T16:53:17Z,2015-31099,0,0,0900006481d9ac55
FDA-2013-E-1573-0004,FDA,FDA-2013-E-1573,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-05T05:00:00Z,2015,11,2015-11-05T05:00:00Z,,2015-11-05T21:36:50Z,,0,0,0900006481d17c3e